These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 11785853

  • 21. Antibiotic susceptibility of pathogens isolated from patients with community-acquired respiratory tract infections in Pakistan--the active study.
    Zafar A, Hussain Z, Lomama E, Sibille S, Irfan S, Khan E.
    J Ayub Med Coll Abbottabad; 2008; 20(1):7-9. PubMed ID: 19024175
    [Abstract] [Full Text] [Related]

  • 22. Antimicrobial drug use and resistance among respiratory pathogens in the community.
    Low DE.
    Clin Infect Dis; 2001 Sep 15; 33 Suppl 3():S206-13. PubMed ID: 11524720
    [Abstract] [Full Text] [Related]

  • 23. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J, House HR, Siegel RE.
    Am J Med; 2005 Jul 15; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [Abstract] [Full Text] [Related]

  • 24. Treatment recommendations for patients with common respiratory tract infections with variables indicative of treatment failure.
    Basri RS, Weiland DA, Ledgerwood GL.
    J Fam Pract; 2008 Feb 15; 57(2 Suppl Managing):S19-23. PubMed ID: 18662525
    [Abstract] [Full Text] [Related]

  • 25. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN, Fritsche TR, Sader HS.
    Diagn Microbiol Infect Dis; 2005 Jun 15; 52(2):129-33. PubMed ID: 15964501
    [Abstract] [Full Text] [Related]

  • 26. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods.
    Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA.
    Ann Emerg Med; 2001 Jun 15; 37(6):690-7. PubMed ID: 11385342
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP.
    Int J Antimicrob Agents; 2007 Feb 15; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [Abstract] [Full Text] [Related]

  • 29. Appropriate antibiotic therapy for community-acquired respiratory tract infections.
    Gerbino PP, Brixner D, Sbarbaro J, Nicolau D.
    Manag Care Interface; 2005 Dec 15; 18(12):41-8. PubMed ID: 16405224
    [Abstract] [Full Text] [Related]

  • 30. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J.
    Int J Clin Pract; 2003 Dec 15; 57(6):519-29. PubMed ID: 12918892
    [Abstract] [Full Text] [Related]

  • 31. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
    Brauers J, Ewig S, Kresken M.
    Pneumologie; 2002 Oct 15; 56(10):605-9. PubMed ID: 12375222
    [Abstract] [Full Text] [Related]

  • 32. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.
    Low DE, Pichichero ME, Schaad UB.
    Clin Pediatr (Phila); 2004 Mar 15; 43(2):135-51. PubMed ID: 15024437
    [Abstract] [Full Text] [Related]

  • 33. Optimal management of community-acquired acute bacterial rhinosinusitis: the allergist's perspective.
    Meltzer EO, Weinstein SF, Zitt MJ.
    Ann Allergy Asthma Immunol; 2006 Mar 15; 96(3):390-7. PubMed ID: 16597072
    [Abstract] [Full Text] [Related]

  • 34. The challenge of prescribing treatment for respiratory tract infections.
    Nicolau DP.
    Am J Manag Care; 2000 May 15; 6(8 Suppl):S419-26. PubMed ID: 10977481
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F, Blais L, Castilloux AM, Scalera A, LeLorier J.
    Can J Clin Pharmacol; 2005 May 15; 12(2):e212-7. PubMed ID: 15998960
    [Abstract] [Full Text] [Related]

  • 36. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May 15; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 37. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J, Martín-Herrero JE, Mykietiuk A, García-Rey C.
    Clin Microbiol Infect; 2006 May 15; 12 Suppl 3():2-11. PubMed ID: 16669924
    [Abstract] [Full Text] [Related]

  • 38. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI.
    Am J Manag Care; 2004 Oct 15; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract] [Full Text] [Related]

  • 39. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ, Zhanel GG.
    Expert Rev Anti Infect Ther; 2006 Dec 15; 4(6):973-80. PubMed ID: 17181414
    [Abstract] [Full Text] [Related]

  • 40. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM.
    Infection; 2005 Jun 15; 33(3):106-14. PubMed ID: 15940410
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.